First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

Documenti analoghi

• Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
  di: Gian Matteo Rigolin, et al.
  Pubblicazione: (2024)
• Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
  di: Paolo Ghia, et al.
  Pubblicazione: (2025)
• Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
  di: Kostas Stamatopoulos, et al.
  Pubblicazione: (2024)
• Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
  di: Raúl Córdoba, et al.
  Pubblicazione: (2026)
• CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
  di: Riccardo Bomben, et al.
  Pubblicazione: (2024)